The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract

Yakovenko E.P.; Agafonova N.A.; Ivanov A.N.; Yakovenko A.V.; Aldiyarova M.A.; Volosheinikova T.V.; Grigor'eva Iu.V.; Soluyanova I.P.

doi:https://doi.org/10.17116/terarkh201688488-92

Yakovenko E.P.

The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Agafonova N.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Ivanov A.N.

Saratovskiĭ meditsinskiĭ institut "REAVIZ"

Yakovenko A.V.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Aldiyarova M.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Volosheinikova T.V.

Clinical Hospital, Department for Presidential Affairs of the Russian Federation, Moscow, Russia

Grigor'eva Iu.V.

Tverskaia gosudarstvennaia meditsinskaia akademiia Minzdrava Rossii

Soluyanova I.P.

Amusk State Medical Academy, Ministry of Health of Russia, Blagoveshchensk, Amursk Region

The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract

Authors:

Yakovenko E.P., Agafonova N.A., Ivanov A.N., Yakovenko A.V., Aldiyarova M.A., Volosheinikova T.V., Grigor'eva Iu.V., Soluyanova I.P.

More about the authors

Journal: Therapeutic Archive. 2016;88(4): 88‑92

DOI: 10.17116/terarkh201688488-92

Read: 21605 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Yakovenko EP, Agafonova NA, Ivanov AN, et al. . The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract. Therapeutic Archive. 2016;88(4):88‑92. (In Russ.)
https://doi.org/10.17116/terarkh201688488-92

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Nottingham Prognostic Index relation to cytokine-producing tumor molecular subtypes in breast cancer. Russian Journal of Preventive Medicine. 2025;(1):63-68

Inflammatory aging. Part 2. Are there diagnostic biomarkers available. Russian Journal of Preventive Medicine. 2025;(1):89-95

Clinical and immunological relationships in patients with early schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42

The effect of the iron III polysaccharide complex use on the cytokines, natriuretic peptide and erythropoietin levels in patients with chronic heart failure accompanied with anemia. Russian Journal of Preventive Medicine. 2025;(3):80-86

Evaluating the efficacy of the Kyoto classification of gastritis in diagnosing Helicobacter pylori infection. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):29-38

Study of serum cytokine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Oncology. 2025;(2):25-29

Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12

Diseases of the upper gastrointestinal tract in pregnancy: what should the gastroenterologist consider?. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):30-42

Associations of genetic polymorphisms in key inflammatory response genes with the risk of chronic apical periodontitis development. Russian Journal of Stomatology. 2025;(2):52-56

Proinflammatory cytokines — as a marker of the effectiveness of neuroprotection in children with perinatal nervous system damage. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):62-66

Abstract:

Rebamipide is a cytoprotесtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration. The major properties of rebamipide include stimulation of prostaglandins and synthesis of muсus glycoproteins, inhibition of reactive oxygen species, inflammatory cytokines, and chemokines, and suppression of neutrophil activation. This paper shows the ability of rebamipide to enhance the efficiency of therapy for Helicobacter pylori-induced infection, to reduce inflammation, including that after infection eradication, to accelerate ulcer healing, and to prevent the progression of preneoplastic lesions.

Keywords:

rebamipidе

gastric cytoprotection

gastric ulcer

prostaglandins

growth faсtor

cytokines

Helicobacter pylori

Helicobacter pylori-associated gastropathy

enteropathy

Authors:

Yakovenko E.P.

The Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Agafonova N.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Ivanov A.N.

Saratovskiĭ meditsinskiĭ institut "REAVIZ"

Yakovenko A.V.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Aldiyarova M.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Volosheinikova T.V.

Clinical Hospital, Department for Presidential Affairs of the Russian Federation, Moscow, Russia

Grigor'eva Iu.V.

Tverskaia gosudarstvennaia meditsinskaia akademiia Minzdrava Rossii

Soluyanova I.P.

Amusk State Medical Academy, Ministry of Health of Russia, Blagoveshchensk, Amursk Region

Close metadata

References:

Rose S, ed. Gastrointestinal and Hepatobiliary pathophysiology. Madison, Connecticut: Fence Greek Publishing, LLC; 1998.
Whittle BJR. Protective mechanisms of the gastric mucosa. In Gustavsson S, Kumar D, Graham DY, eds. The stomach. Edinburgh, London, Madrid: Churchill Livingstone; 1992:81-101.
Sol AH. Peptic ulcer and its complications. In Sleisenger M, Fordtrans JS, eds. Gastrointestinal and Liver Disease. Philadelphia-London-Toronto-Monreal-Sydney-Tokyo; 2003.
Grigor'ev P, Yakovenko A. Klinicheskaya gastroenterologiya. 3-nd edition. M.: MIA; 2004. (In Russ.)
Feldman M, Scharschmidt BF, Sleisenger MH, Fordtran JS, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. W.B. Saunders Company; 1998.
Yakovenko E, Yakovenko A, Illarionova Yu, Ivanov A, Agafonova N, Pryanishnikova A, Soluyanova I. Proton pump inhibitors in prevention and treatment of stressful ulcers. Lechashchii vrach. 2010;(2):52-55. (In Russ.)
Yakovenko E, Yakovenko A, Illarionova Yu, Agafonova N, Lavrent'eva S, Ivanov A, Pryanishnikova A, Krasnolobova L. Pantoprazol in treatment of acid-associated diseases. Farmateka. 2012;2:45-50. (In Russ.)
Kononov A. The heterogeneity of the inflammatory response in the population with Helicobacter pylori infection. Pediatriya. 2002;2(suppl.):124-130. (In Russ.)
Prichard P, Walt R, Chapman R. Drugs for the GUT. A practical guide to gastrointestinal and liver therapy. London, Philadelphia, Toronto, Sydney: WB Saunders company limited; 1998.
Yakovenko A, Grigor'ev P, Yakovenko E, Agafonova N, Pryanishnikova A, Ivanov A, Aldiyarova M, Soluyanova I, Anashkin V, Oprishchenko I. Citoprotective drugs in treatment of gastric diseases. The optimal approach to the selection of the drug. Klinicheskaya i eksperemental’naya gastroenterologiya. 2006;2:56-60. (In Russ.)
Arakawa T, Higuchi K, Fujiwara Y et al. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig Dis Sci. 2005;50(1):S3-S11. doi:10.1007/s10620-005-2800-9.
Nebiki H, Higuchi K, Arakawa T et al. Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci. 1998;(43):203-206.
Haruma K, Ito М, Kido S et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47:862-867. doi:10.1023/a:1014716822702.
Higuchi K, Arakawa T, Nebiki H et al. Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci. 1998;43:99S-106S.
Kim H, Seo JY, Kim KH. Inhibition of lipid peroxidation, NFkappaB activation and IL-8 production bу rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci. 2000;45:621-628. doi:10.1023/a:1005474013988.
Takaishi O, Arakawa T, Yamasaki K, Fujiwara Y, Uchida T, Tominaga K, Watanabe T, Higuchi K, Fukuda T, Kobayashi K and Kuroki T. Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Dig Dis Sci. 1998;43:78s-82s.
Мatysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M. Alterations of epithelial permeability by HeIicobacter and IL-Iβ in vitro: protective effect of rebamipide. Dig Dis Sсi. 2001;46:1558-1566. doi:10.1023/a:1010664626431.
Nebiki H, Atakawa T, Higuchi K, Kobayashi K. Quality of ulcer healing influences the relapse of gastic ulcers in humans. J Gastroentrol Hepatol. 1997;12:109-114. doi:10.1111/j.1440-1746.1997.tb00393.x.
Takayama M. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol. 2013;19(34):5706-5712. doi:10.3748/wjg.v19.i34.5706.
Ishihara K, Komuro Y, Nishiyama N et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independet mechanism. Drag Res. 1992;42:1462-1466.
Watanabe S, Wang X-E, Hirose M. et al. Effects of rebamipide on bile acid induced inhibition of gastric epithelial repair in a rabbit cell culture model. Aliment Pharmacol Ther. 1996;10(6):927-932. doi:10.1046/j.1365-2036.1996.105276000.x.
Tarnawski A., Arakawa T., Kobayashi K. Rebamipide treatment activates EGF and its receptor expression in normal and ulcerated gastric mucosa. The molecular mechanism of its ulcer healing action. J Gastroenterol Hepatol. 1997;12(suppl):A221.
Naito Y, Yoshikawa T, Iinuma S et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittelforschung. 1996;46:698-700.
Tarnawski A, Pai R, Chiou S, Chai J, Chu E. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005;334(1):207-212. doi:10.1016/j.bbrc.2005.05.204.
Hawkey C. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003;52(4):600-608. doi:10.1136/gut.52.4.600.
Endo H, Sakai E, Higurashi T et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833-838. doi:10.1016/j.dld.2012.05.016.
Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta. 2010;411(7-8):459-466. doi:10.1016/j.cca.2009.12.026.
Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol. 2001;16(10):1112-1119. doi:10.1046/j.1440-1746.2001.02592.x.
Kurokawa S, Katsuki S, Fujita T et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2013;49(2):239-244. doi:10.1007/s00535-013-0805-2.